Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02845297
Title Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (?65 Years) AML Patients
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Johns Hopkins Oncology Center Baltimore Maryland 21231-2410 United States Details
University of North Carolina Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599 United States Details
Medical University of South Carolina Hollings Cancer Center Charleston South Carolina 29425 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field